Dr. Michael D. Williams, MD
Gastroenterology (Gastroenterology Physician)
210 Portland St Ste 100
Columbia, MO 65201
Who else practices at this address →
Boone County is a federal dental shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Missouri, Columbia School of Medicine (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 719
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: University of Missouri, Columbia School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
MO license 2017008968
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Boone Hospital Center Columbia, MO
Medical groups
- Gastrointestinal Associates, LLC (30 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 719
- Services billed
- 23,136
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, vedolizumab, 1 mg | 20,400 | 12 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 492 | 47 |
| Pathology examination of tissue using a microscope, intermediate complexity | 489 | 212 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 295 | 47 |
| Special stained specimen slides to examine tissue including interpretation and report | 193 | 80 |
| Special stained specimen slides to identify organisms including interpretation and report | 152 | 78 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 147 | 144 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 142 | 134 |
| Biopsy of large bowel using a flexible endoscope | 136 | 133 |
| Established patient office or other outpatient visit, 30-39 minutes | 113 | 86 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 18 companies reported 138 payments worth $4,567 in total to this clinician.
| Phathom Pharmaceuticals, Inc. | $1,892 |
|---|---|
| AbbVie Inc. | $745 |
| Janssen Biotech, Inc. | $360 |
| Takeda Pharmaceuticals U.S.A., Inc. | $273 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $246 |
| Celltrion USA Inc. | $215 |
| Aimmune Therapeutics, Inc. | $155 |
| Genzyme Corporation | $113 |
| Food and Beverage | $2,801 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $1,720 |
| Education | $32.27 |
| Travel and Lodging | $14.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Phathom Pharmaceuticals, Inc. Mar 5, 2025 | Compensation for services other than consulting (speaking, faculty) VOQUEZNA · Gastroenterology | $1,720 |
| Novo Nordisk Inc May 22, 2025 | Education in-kind | $32.27 |
| Phathom Pharmaceuticals, Inc. Apr 2, 2025 | Travel and Lodging VOQUEZNA · Gastroenterology · travel to Columbia, MO | $14.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $366,526 in research payments for these studies, mostly to the institutions running them.
- Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
AbbVie Inc. · Recruiting · NCT06548542 - A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepati…
Boehringer Ingelheim International GmbH - A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/…
Boehringer Ingelheim International GmbH - M24-885 - Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD)
AbbVie Inc. - Study of DONQ52 in Active Celiac Disease
Chugai Pharmaceutical Co., Ltd. - Caris Biorepository Research Protocol
Caris Mpi, Inc. · Recruiting · NCT01499394 - Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.